Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.
Bioventures Opportunities GP I, LLC YK, a 10% owner of $CERO ($CERO), sold 1,343,801 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Bioventures Opportunities GP I, LLC YK, a 10% owner of $CERO ($CERO), sold 1,236,874 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
CERo Therapeutics appoints Chris Ehrlich as CEO, advancing cancer immunotherapy development, including plans for clinical trials in 2025.Quiver AI SummaryCERo Therapeutics Holdings, Inc. has announced...
CERo Therapeutics received FDA clearance for Phase 1 trials of CER-1236 in acute myelogenous leukemia.Quiver AI SummaryCERo Therapeutics Holdings, Inc. announced that the U.S. FDA has cleared its Investigational...
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that